Drug transporter - enzyme crossroads: Does OATP2B1 shape Cyp3a-driven midazolam metabolism in rats?

OATP2B1, encoded by SLCO2B1, is an uptake transporter in liver. Humanized SLCO2B1+/+ rats showed increased hepatic Cyp3a1 expression compared to rSlco2b1−/− rats. To assess the impact of humanization on Cyp3a activity, we conducted a phenotyping study applying midazolam in SLCO2B1+/+ and rSlco2b1−/-...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:European journal of pharmaceutical sciences Ročník 215; s. 107343
Hlavní autoři: Paloumpis, Nikolaos, Rysz, Marta, Bianchi, Noemi, Seibert, Isabell, Kinzi, Jonny, Schäfer, Anima M., Brecht, Karin, Ricklin, Daniel, Meyer zu Schwabedissen, Henriette E.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Netherlands Elsevier B.V 01.12.2025
Témata:
Animals
Cyp3a1
Cyp3a2
Cytochrome P-450 CYP3A - genetics
Cytochrome P-450 CYP3A - metabolism
Humans
Liver - metabolism
Male
Microsomes, Liver - metabolism
Midazolam
Midazolam - analogs & derivatives
Midazolam - blood
Midazolam - metabolism
Midazolam - pharmacokinetics
OATP2B1
Organic Anion Transporters - genetics
Organic Anion Transporters - metabolism
Rat model
Rats
Rats, Sprague-Dawley
Cyp3a1
Rat model
Midazolam
Cyp3a2
OATP2B1
ISSN:0928-0987, 1879-0720, 1879-0720
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:OATP2B1, encoded by SLCO2B1, is an uptake transporter in liver. Humanized SLCO2B1+/+ rats showed increased hepatic Cyp3a1 expression compared to rSlco2b1−/− rats. To assess the impact of humanization on Cyp3a activity, we conducted a phenotyping study applying midazolam in SLCO2B1+/+ and rSlco2b1−/- rats. Analysis of the serum levels and pharmacokinetic parameters for midazolam, 1′-hydroxymidazolam and 4-hydroxymidazolam revealed no significant differences between humanized and rSlco2b1−/− rats, indicating minimal impact of genotype on systemic exposure. In contrast, ex vivo experiments with liver microsomes from untreated male SLCO2B1+/+ and rSlco2b1−/- rats, showed slightly higher Cyp3a activity in the knockout group. To resolve this apparent discrepancy, we characterized midazolam metabolism using recombinant enzyme systems, where we found Cyp3a2 to exhibit a higher metabolic capacity for midazolam when comparing formation of both metabolites. Determination of transcript levels of Cyp3a isoforms in rat livers revealed consistently higher mRNA expression of Cyp3a2 irrespective of genotype. These findings suggest that Cyp3a2 is the predominant isoform responsible for midazolam metabolism in rats. The modestly elevated microsomal activity in rSlco2b1−/- rats is therefore most likely attributable to the subtle variation in Cyp3a2 abundance. In conclusion, our findings indicate that even if OATP2B1 affects hepatic abundance of Cyp3a1 this does not translate into relevant changes in pharmacokinetics of midazolam most likely due to the dominance of Cyp3a2 in its metabolism. [Display omitted]
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0928-0987
1879-0720
1879-0720
DOI:10.1016/j.ejps.2025.107343